Brown County and C. Reiss agree to lease Pulliam property, but not for coal
Many eyes were on Green Bay and Brown County this week as officials inched closer to a deal that had $15 million at stake. The deal marks a historic milestone to a decades-long effort to relocate the coal piles from its 125-year home at 115 W. Mason St. Under the agreement, C. Reiss will lease the former Pulliam power plant to store salt and other bulk commodities instead of coal.
The terms still fulfill decades of community leaders' goal to free up prime riverfront property for industrial, commercial and residential use at the mouth of the Fox River.
The Brown County Board unanimously voted to approve the terms of the agreement. Board member Dixon Wolfe was not at the meeting.
Former Green Bay mayors Jim Schmitt and Paul Jadin awaited the County Board's momentous vote, along with state Sens. Eric Wimberger, R-Oconto, and Jamie Wall, D-Green Bay; and state Reps. David Steffen, R-Howard; Ben Franklin, R-De Pere; Ryan Spaude, D-Ashwaubenon; and Amaad Rivera-Wagner, D-Green Bay.
C. Reiss will lease 16 acres of the Pulliam site to store bulk commodities. The coal piles will be housed at the Fox River Terminal. Lease payments with a rate of $350,000 per year with increases every five years during the first 25 years based on the Consumer Price Index. The length of the lease is 60 years and can be extended. The lease needs to be executed by Sept. 25, according to the agreement.
The new plan is a notable shift from previous proposals that had intended to make the Pulliam site the new home of the coal piles.
Key parties were sorting out the agreement just a few minutes before starting the County Board meeting June 5, Buckley said ahead of the vote.
The board voted on the deal June 5, just hours before the deadline to retain the $15 million state grant. The Wisconsin Department of Administration gave the County Board until June 6 to approve terms of a deal after extending the deadline from the end of May.
Brown County agrees to buy the 43.75-acre Pulliam site for $2.7 million in January 2021.
Brown County approves the Pulliam site purchase and agrees to sell almost 10 acres of the site to GLC Minerals for an expansion in February 2021.
Gov. Tony Evers awards the city and county a $15 million Neighborhood Investment Fund Program grant funded through American Rescue Plan Act dollars in March 2022.
Former Transportation Secretary Pete Buttigieg presents the county with a federal $10.1 million Port Infrastructure Development grant to support the project in May 2023.
Offers, counteroffers and rejections began in mid-December 2024 when the county officials and C. Reiss tentatively agreed to a $26 million plan that would lease 14.5 acres of the Pulliam property to C. Reiss for up to 75 years at a rate of $110,000 per year with an annual 2.5% increase.
The County Board on Dec. 18, 2024, approved modified terms that reduced the lease to 40 years, changed the portion of the Pulliam property C. Reiss would use and added air quality compliance measures. C. Reiss considered the changes a rejection of the negotiated deal.
The county's Port of Green Bay published a request for companies' general interest in using the new port site envisioned for the Pulliam property in January 2025. C. Reiss was one of eight to respond with a $28.5 million proposal to improve and use the Pulliam site for coal storage.
C. Reiss in mid-March formally rejected the County Board's terms and proposed the county and company spend several months negotiating a deal. The County Board on March 19 rejected the company's offer.
The county instead sought to shift negotiations to two alternate sites for coal storage, saying the Pulliam property's future use would be determined by the request for interest process.
State officials in March gave the county, company and city a May 30 deadline to reach a deal to relocate the coal piles to the Pulliam site or lose the $15 million grant.
Two new proposals emerged in late May as the county, company and city jointly met to discuss options and ideas.
State Sen. Eric Wimberger, R-Oconto, on May 23 asked the state to extend the May 30 deadline and the Department of Administration did so on May 30, giving the parties until June 3.
Brown County and C. Reiss reached a tentative agreement June 3 and announced the parties would put together the terms in writing June 4 and 5.
More: Who still uses coal? Answers to questions about Green Bay coal piles and the possible move
More: Brown County, C. Reiss strike deal to move coal piles after extensive negotiations
Press-Gazette reporter Jeff Bollier contributed to this report.
Contact Benita Mathew at bmathew@gannett.com.
This article originally appeared on Green Bay Press-Gazette: Brown County votes on C. Reiss deal for coal piles
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Lab Equipment Market and Supply Chain Forecasts 2025-2030 Featuring Eppendorf, Beckman Coulter, Agilent Technologies, Thermo Fisher Scientific, Waters Corp. & More
The Lab Equipment Market is projected to grow at 7% CAGR, driven by increased pharmaceutical R&D, rising chronic disease prevalence, and growing demand for biologics Lab Equipment Market Dublin, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The "Lab Equipment Market - Forecasts from 2025 to 2030" has been added to offering. The global lab equipment market foresees significant expansion, projected to grow from USD 19.507 billion in 2025 to USD 27.310 billion by 2030, registering a CAGR of 6.96%. This growth trajectory is underpinned by dynamic factors, anticipated to propel the market. Pharmaceutical R&D investments are a primary catalyst, with global spending reaching USD 280 billion in 2024, focusing on groundbreaking drugs and biologics. Streamlined clinical trial processes, exemplified by the European Medicines Agency's fast-track schemes reducing approval times, emphasize the demand for cutting-edge lab equipment essential for drug discovery. Chronic disease prevalence, including cancer, diabetes, and cardiovascular conditions, further accelerates market demand. In 2024, the U.S. recorded 1.9 million new cancer cases, underlining the urgency for advanced diagnostics and drug development. The rising chronic disease burden globally, particularly in aging populations, intensifies the need for sophisticated lab tools. Biologics, derived from living organisms, represent a rapidly growing market segment, accounting for a substantial portion of the pharmaceutical pipeline in 2024. With 40% of clinical trials targeting biologics, specialized lab equipment becomes indispensable for development and testing, driving market expansion. Segment-wise, the sensing equipment category, including spectrometers and conductivity meters, dominates due to its pivotal role in precise diagnostics and drug development. Biopharmaceutical companies hold the largest market share, bolstered by substantial R&D budgets and specialized equipment requirements. Government and academic institutions also contribute significantly, with increased public funding for health research. Geographically, North America leads with over 35% of global lab equipment revenue, supported by advanced healthcare infrastructure. Meanwhile, Asia-Pacific emerges as the fastest-growing region, buoyed by a rising incidence of chronic diseases and increased pharmaceutical investments. Europe's growth is reinforced by regulatory backing for innovative therapies. Key industry players, including Eppendorf AG and Thermo Fisher Scientific Inc., dominate due to robust brand reputations and innovative product offerings. For instance, in 2023, Thermo Fisher launched advanced spectrometry equipment for biologics research, enhancing precision and driving market leadership. Nevertheless, the market faces challenges such as high costs of advanced equipment and the requisite skilled personnel for operating complex systems. Regulatory requirements often delay market entry, necessitating continuous innovation to meet compliance standards. This report provides: Market insights spanning major and emerging regions, focusing on consumer tendencies and industry verticals. Understanding of strategies employed by global key players. Exploration of market drivers and future trends. Actionable insights for strategic business decisions. Catering to startups, research institutions, SMEs, and large enterprises. Report Highlights: Historical data (2022-2024) and forecast (2025-2030). Analysis of growth opportunities, challenges, and regional trends. Strategies and market share analysis of leading companies. Revenue growth projections by segments and regions. Company profiling, strategic developments, and product information. Lab Equipment Market Segmentation: By Type: Analytical Instruments, General Lab Equipment, Measuring & Monitoring Devices, Specialty Equipment, Support Equipment. By End-User: Academic & Research Institutes, Biopharmaceutical & Pharmaceutical Companies, Healthcare & Diagnostic Labs, Government & Regulatory Bodies, Industrial & Manufacturing, Others. By Geography: North America, South America, Europe, Middle East and Africa, Asia-Pacific. Key Attributes Report Attribute Details No. of Pages 150 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $19.51 Billion Forecasted Market Value (USD) by 2030 $27.31 Billion Compound Annual Growth Rate 6.9% Regions Covered Global Key Topics Covered1. EXECUTIVE SUMMARY2. MARKET SNAPSHOT2.1. Market Overview2.2. Market Definition2.3. Scope of the Study2.4. Market Segmentation3. BUSINESS LANDSCAPE3.1. Market Drivers3.2. Market Restraints3.3. Market Opportunities3.4. Porter's Five Forces Analysis3.5. Industry Value Chain Analysis3.6. Policies and Regulations3.7. Strategic Recommendations4. TECHNOLOGICAL OUTLOOK5. GLOBAL LAB EQUIPMENT MARKET BY TYPE5.1. Introduction5.2. Analytical Instruments5.3. General Lab Equipment5.4. Measuring & Monitoring Devices5.5. Specialty Equipment5.6. Support Equipment6. GLOBAL LAB EQUIPMENT MARKET BY END-USER6.1. Introduction6.2. Academic & Research Institutes6.3. Biopharmaceutical & Pharmaceutical Companies6.4. Healthcare & Diagnostic Labs6.5. Government & Regulatory Bodies6.6. Industrial & Manufacturing6.7. Others7. GLOBAL LAB EQUIPMENT MARKET BY GEOGRAPHY7.1. Introduction7.2. North America7.3. South America7.4. Europe7.5. Middle East and Africa7.6. Asia-Pacific8. COMPETITIVE ENVIRONMENT AND ANALYSIS8.1. Major Players and Strategy Analysis8.2. Market Share Analysis8.3. Mergers, Acquisitions, Agreements, and Collaborations8.4. Competitive Dashboard9. COMPANY PROFILES9.1. Eppendorf AG9.2. Beckman Coulter, Inc.9.3. Agilent Technologies, Inc.9.4. Thermo Fisher Scientific Inc.9.5. Waters Corporation9.6. F. Hoffmann-La Roche Ltd9.7. Shimadzu Corporation9.8. Bio-Rad Laboratories, Inc.9.9. PerkinElmer Inc.10. APPENDIX For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Lab Equipment Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
4 hours ago
- Yahoo
Medtronic PLC (MDT) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Raised EPS Guidance
This article first appeared on GuruFocus. Revenue: $8.6 billion, grew 8.4% reported and 4.8% organic. Cardiovascular Growth: 7% growth, driven by nearly 50% growth in cardiac ablation solutions. Neuroscience Growth: 3% growth, with mid-single-digit growth in cranial and spinal technologies. Medsurge Growth: 2% growth, with high single-digit growth in advanced energy. Diabetes Growth: 8% growth, including 11% growth in international markets. Adjusted Gross Margin: 65.1%, down 80 basis points year over year. Adjusted Operating Margin: 23.6%. Adjusted EPS: $1.26, $0.03 above the midpoint of guidance. R&D Investment: Up 7.7%, 100 basis points ahead of revenue growth. Fiscal Year '26 Organic Revenue Growth Guidance: Approximately 5%. Fiscal Year '26 EPS Guidance: Raised to $5.60 to $5.66. Warning! GuruFocus has detected 7 Warning Signs with ODFJF. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Medtronic PLC (NYSE:MDT) reported consistent mid-single-digit revenue growth, with EPS exceeding guidance. The cardiovascular segment showed strong performance, with nearly 50% growth in cardiac ablation solutions driven by innovative product rollouts. The company raised its EPS guidance for the full year, reflecting confidence in continued financial acceleration. Medtronic PLC (NYSE:MDT) is poised for growth in the second half of the fiscal year, with several product launches and market expansions planned. The planned separation of the diabetes business is expected to be EPS accretive and improve operating margins, enhancing shareholder value. Negative Points Neuroscience growth was below trend due to specialty therapies, though improvements are expected in subsequent quarters. The Medsurge segment grew only 2%, aligning with expectations but indicating slower growth compared to other segments. The diabetes segment faced challenges in the US market, with growth primarily driven by international sales. Gross margin decreased by 80 basis points year-over-year, impacted by business mix and manufacturing ramp-up costs. Tariffs are expected to have a negative impact of approximately $185 million for fiscal '26, though this is an improvement from previous estimates. Q & A Highlights Q: Can you provide an update on the CAS business and its impact on overall growth? A: Geoff Martha, CEO, explained that the CAS business is accelerating, with 72% growth in the US. The company is confident in its ability to accelerate growth over FY26, with new technologies and a strong pipeline expected to have an outsized impact on US growth. Thierry Pieton, CFO, added that the US growth was impacted by slower growth in certain areas, but expects improvement as new products ramp up. Q: What is the purpose of the new Board committees focused on growth and operations? A: Geoff Martha, CEO, stated that the committees will provide focus and support management, particularly in growth and operational performance. The committees will include new directors with deep medtech experience and will have more frequent interactions with management to drive focus and execution. Q: Is the $2 billion target for annual CAS sales achievable in fiscal '26? A: Geoff Martha, CEO, confirmed that the target of an additional $1 billion on top of the FY25 base is on track. While it might extend into FY27, the company is confident in achieving this near-term goal. Q: How will the new directors and committees impact capital allocation and EPS growth? A: Geoff Martha, CEO, emphasized that the company is entering a new chapter focused on value creation. This includes more M&A, portfolio optimization, and increased investment in growth drivers. The committees will help ensure these strategies are executed effectively. Q: Can you discuss the potential impact of renal denervation on Medtronic's growth profile? A: Geoff Martha, CEO, highlighted that renal denervation (RDN) is a significant growth opportunity, with a massive patient population. The company is investing in market development and expects RDN to be a major driver of growth, potentially becoming one of the largest product categories for Medtronic. Q: What is the status of the diabetes business separation and its impact on growth? A: Thierry Pieton, CFO, confirmed that the separation is on track, with completion expected within 15 months. The diabetes business is entering a strong innovation cycle, and the separation is expected to be a value-creating event for shareholders. Q: How is the Hugo robotic system performing in international markets, and what are the expectations for the US launch? A: Michael Marinaro, EVP, stated that Hugo is performing well in over 30 countries, with significant double-digit growth in current accounts. The system's modular design and partnership approach are key strengths. The company is preparing for the US launch, with FDA approval processes underway. Q: What are the growth prospects for Medtronic's slower-growing businesses? A: Geoff Martha, CEO, noted that several slower-growing businesses have specific growth accelerators, such as new products and market expansions. The company is focused on driving growth across all segments, with organic and inorganic strategies. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
This Quantum Computing Stock Just Made an AI Breakthrough
Key Points The unique capabilities of quantum computers could accelerate the evolution of artificial intelligence (AI). In a bid to advance the AI field, D-Wave Quantum developed a new tool kit integrating AI with quantum devices. Sales of D-Wave's tech delivered $18.1 million, a 289% year-over-year increase through the first half of 2025. 10 stocks we like better than D-Wave Quantum › Artificial intelligence (AI) is a hot sector with forecasts predicting the market to grow from $244 billion in 2025 to over $800 billion by 2030. This astounding growth could be supercharged by the advent of quantum computers. Quantum machines possess the ability to complete intricate calculations that surpass the capacities of classic computers. Marrying quantum devices with AI opens up new possibilities not attainable today. That's what makes the release of AI tools by D-Wave Quantum (NYSE: QBTS) a significant development. The tool set enables integration with D-Wave's quantum computers. Does this melding of AI and quantum tech suggest D-Wave stock is worth investing in? To assess the opportunity, let's look into what the company is doing and whether now is the time to buy shares in D-Wave. Details of D-Wave's new AI features On Aug. 4, D-Wave rolled out new tools allowing AI software developers to experiment with its quantum computer processors. This tool kit integrates the company's quantum systems with PyTorch, a framework for building AI models that has become a leader in the space. D-Wave's tools provide a PyTorch neural network module, enabling the development and training of AI models using a quantum computer. Today, these models require massive computational power and energy. As a result, the cost to build AI is escalating. According to Dr. Alan Baratz, CEO of D-Wave, "Quantum computing's integration with AI and machine learning could offer scalable, energy-efficient solutions to address these issues and potentially offer enhanced AI capabilities." The company is already working with customers to advance the use of AI with quantum machines. For instance, it's partnering with the pharmaceutical division of Japan Tobacco to combine quantum systems and AI in the drug-discovery process. The impact of D-Wave's tech on financial performance Delivering the ability of quantum computers to assist with AI development is an impressive milestone. But how have D-Wave's technological advances helped the company? Through the first half of 2025, D-Wave's sales have skyrocketed 289% year over year to $18.1 million. Its Japan Tobacco partnership is an example of broader customer demand, as orders in the Asia-Pacific region have grown 83% over the past 12 months. Clients in the area seek to apply D-Wave's quantum tech to AI and other business challenges. As a result, the company is holding its first quantum computing conference in Tokyo on Sept. 17. Moreover, D-Wave's gross margin ticked up to 63.8% in the second quarter from 63.6% in the prior year. You want to see gross margin steadily rise, as it means the company is improving cost management and thereby growing gross profit, which improved 42% year over year for D-Wave to $2 million off $3.1 million in Q2 sales. However, D-Wave doesn't operate a profitable business. Its Q2 loss from operations reached $26.5 million, up from a loss of $18.8 million in 2024, as research and development costs grew more than 50% year over year to $12.7 million. The increase in D-Wave's expenses are to be expected, since developing cutting-edge technology is not easy -- or cheap. In fact, many tech companies operate at a loss for years as they pour earnings into building up their businesses. So D-Wave's situation is not uncommon. In addition, the company has amassed a sizable war chest of $819.3 million in cash and equivalents at the end of Q2. This brought Q2 total assets to $843.6 million versus total liabilities of $149.3 million. The solid balance sheet funds operations in the short term while the company ramps up sales and seeks strategic acquisitions. Evaluating whether to invest in D-Wave stock Do these factors mean now is the time to invest in D-Wave stock? One consideration is share-price valuation. This can be assessed using the price-to-sales (P/S) ratio, which measures how much investors are willing to pay for every dollar of revenue generated over the trailing 12 months. The chart shows D-Wave's P/S multiple has gone up since it plunged in April along with the broader stock market due to President Trump's aggressive tariff approach. As of Aug. 15, it's near previous peaks, suggesting D-Wave shares are pricey. The other consideration is that quantum computers suffer challenges that prevent them from becoming scalable and cost effective. These devices use atomic particles to perform computations, but the particles are sensitive to the slightest environmental disruption, such as vibrations or temperature fluctuations. D-Wave is working to overcome these challenges but so are its many competitors, and it could take years to solve the issues. As a result, investing in D-Wave is only for those with a high risk tolerance. A judicious approach is to wait for D-Wave's share price to drop before deciding to buy. Should you buy stock in D-Wave Quantum right now? Before you buy stock in D-Wave Quantum, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and D-Wave Quantum wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This Quantum Computing Stock Just Made an AI Breakthrough was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
